UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 08/2017, Volume 27, Issue 16, pp. 3872 - 3877
Antibacterial activity | Erythromycin-resistant bacteria | Synthesis | Bacterial resistance | 1,2,3-Triazol azithromycin analogs | Streptococcus pneumoniae - drug effects | Azithromycin - chemistry | Streptococcus pyogenes - drug effects | Escherichia coli - drug effects | Structure-Activity Relationship | Azithromycin - analogs & derivatives | Azithromycin - pharmacology | Anti-Bacterial Agents - chemical synthesis | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-Bacterial Agents - chemistry | Azithromycin - chemical synthesis | Anti-Bacterial Agents - pharmacology | Molecular Structure | Staphylococcus aureus - drug effects | Drug resistance in microorganisms | Pneumonia | Bacterial pneumonia | Azithromycin | Bacteria | Antibacterial agents | Child care | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9842, pp. 660 - 667
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Errors of metabolism | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Prevention and actions | Biological and medical sciences | Metabolic diseases | Medical sciences | Miscellaneous hereditary metabolic disorders | Double-Blind Method | Drug Administration Schedule | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Treatment Outcome | Secondary Prevention | Azithromycin - administration & dosage | Cystic Fibrosis - complications | Vital Capacity - drug effects | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Bronchiectasis - prevention & control | Quality of Life | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - administration & dosage | Bronchiectasis - physiopathology | Bronchiectasis - etiology | Prevention | Usage | Bronchiectasis | Research | Azithromycin | Medical research | Antibiotics | Drug therapy | Mortality | Streptococcus infections | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2013, Volume 309, Issue 12, pp. 1251 - 1259
LOW-DOSE AZITHROMYCIN | LONG-TERM AZITHROMYCIN | PSEUDOMONAS-AERUGINOSA | DOUBLE-BLIND | GEORGES RESPIRATORY QUESTIONNAIRE | STAPHYLOCOCCUS-AUREUS | PULMONARY-FUNCTION | PLACEBO-CONTROLLED TRIAL | MACROLIDE RESISTANCE | HEALTH-STATUS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Errors of metabolism | General aspects | Respiratory system : syndromes and miscellaneous diseases | Biological and medical sciences | Metabolic diseases | Medical sciences | Miscellaneous hereditary metabolic disorders | Pneumology | Sputum - microbiology | Double-Blind Method | Bacterial Infections - etiology | Humans | Middle Aged | Respiratory Tract Infections - prevention & control | Drug Resistance, Bacterial | Male | Inflammation | Lung - physiopathology | Biomarkers - blood | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Bacterial Infections - prevention & control | Bronchiectasis - complications | Azithromycin - therapeutic use | Quality of Life | Adult | Female | Respiratory Tract Infections - etiology | Aged | Anti-Bacterial Agents - adverse effects | Respiratory Function Tests | Clinical trials | Cystic fibrosis | Antibiotics | Medical treatment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Kemija u industriji; ÄŤasopis kemiÄŤara i tehnologa Jugoslavije, ISSN 0022-9830, 12/2011, Volume 60, Issue 12, pp. 603 - 617
Journal Article
Travel medicine and infectious disease, ISSN 1477-8939, 05/2020, Volume 35, pp. 101738 - 101738
COVID-19 | SARS-CoV-2 | Hydroxychloroquine | Azithromycin | Public, Environmental & Occupational Health | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Hydroxychloroquine - therapeutic use | Pandemics | Follow-Up Studies | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Azithromycin - administration & dosage | Hydroxychloroquine - adverse effects | Coronavirus Infections - mortality | Viral Load | Young Adult | Time Factors | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Retrospective Studies | Drug Therapy, Combination | France | Antiviral Agents - therapeutic use | Treatment Outcome | Antiviral Agents - administration & dosage | Hydroxychloroquine - administration & dosage | Azithromycin - adverse effects | Azithromycin - therapeutic use | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Adolescent | Aged | Pneumonia, Viral - mortality | Betacoronavirus - genetics | Pneumonia, Viral - virology | Pneumonia | Toxicity | Infections | Receptors | Electrocardiography | Serum | Drug dosages | Failure | Ventilators | Oxygen therapy | Nucleotide sequence | Complications | Coronaviruses | Patients | Polymerase chain reaction | Severe acute respiratory syndrome coronavirus 2 | Persistence | Infectious diseases | Hospitals | DNA | Fatalities | Electrolytes | Skin | Symptoms | Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2020, Volume 323, Issue 24, pp. 2493 - 2502
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxychloroquine - therapeutic use | Arrhythmias, Cardiac - chemically induced | Pandemics | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Hydroxychloroquine - adverse effects | Coronavirus Infections - mortality | COVID-19 | Young Adult | SARS-CoV-2 | Betacoronavirus | Adult | Female | Retrospective Studies | Drug Therapy, Combination | New York | Anti-Infective Agents - adverse effects | Hospital Mortality | Proportional Hazards Models | Anti-Infective Agents - therapeutic use | Logistic Models | Hospitalization | Azithromycin - adverse effects | Azithromycin - therapeutic use | Adolescent | Heart Arrest - etiology | Aged | Pneumonia, Viral - mortality | Hospital patients | Care and treatment | Hydroxychloroquine | Medical examination | Patient outcomes | Azithromycin | Drug therapy, Combination | Drug therapy | Health aspects | Testing | Heart | Arrhythmia | Health services | Viral diseases | Medical records | Metropolitan areas | Regression models | Electrocardiography | EKG | Statistical analysis | Mortality | Diabetes mellitus | Pharmacology | Regression analysis | Coronaviruses | Chemical compounds | Patients | Respiratory rate | Statistical models | Models | Aspartate aminotransferase | Respiration | Prolongation | Index Medicus | Abridged Index Medicus
Journal Article
Thorax, ISSN 0040-6376, 04/2013, Volume 68, Issue 4, pp. 322 - 329
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Azithromycin - administration & dosage | Asthma - drug therapy | Disease Progression | Anti-Bacterial Agents - therapeutic use | Azithromycin - therapeutic use | Adult | Female | Drug Therapy, Combination | Anti-Bacterial Agents - administration & dosage | Prevention | Respiratory tract infections | Care and treatment | Azithromycin | Dosage and administration | Research | Asthma | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 01/2019, Volume 19, Issue 1, pp. e14 - e25
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Pneumococcal Infections - drug therapy | Prevalence | Humans | Child, Preschool | Infant | Male | Azithromycin - administration & dosage | Anti-Bacterial Agents - therapeutic use | Trachoma - epidemiology | Female | Pneumococcal Infections - microbiology | Anti-Bacterial Agents - adverse effects | Drug Resistance, Bacterial - drug effects | Chlamydia trachomatis - drug effects | Child | Streptococcus pneumoniae - drug effects | Administration, Oral | Trachoma - drug therapy | Treatment Outcome | Azithromycin - adverse effects | Macrolides - adverse effects | Azithromycin - therapeutic use | Adolescent | Macrolides - therapeutic use | Anti-Bacterial Agents - administration & dosage | Trachoma - microbiology | Mortality | Bias | Azithromycin | Trachoma | Antimicrobial agents | Systematic review | Chlamydia trachomatis | Organisms | Grey literature | Drug resistance | Antiinfectives and antibacterials | Streptococcus infections | Studies | Sexually transmitted diseases | Reviews | E coli | Children | Antimicrobial resistance | Index Medicus
Journal Article
Emerging infectious diseases, ISSN 1080-6040, 04/2019, Volume 25, Issue 4, pp. 841 - 843
alternative treatment | Toxoplasma gondii | HIV | Japan | parasites | azithromycin | clindamycin | meningitis/encephalitis | Toxoplasmic encephalitis | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Toxoplasmosis, Cerebral - diagnosis | Toxoplasmosis, Cerebral - parasitology | Humans | Middle Aged | Male | Treatment Outcome | Azithromycin - administration & dosage | Toxoplasmosis, Cerebral - drug therapy | Clindamycin - therapeutic use | Magnetic Resonance Imaging | Azithromycin - therapeutic use | Clindamycin - administration & dosage | Antiprotozoal Agents - administration & dosage | Biomarkers | Toxoplasma - drug effects | Antiprotozoal Agents - therapeutic use | Drug Therapy, Combination | Encephalitis | Sulfadiazine | Care and treatment | Clindamycin | World health | Azithromycin | Pyrimethamine | Drug therapy, Combination | meningitis | Combination of Clindamycin and Azithromycin as Alternative Treatment for | Research Letter
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 20, pp. 1881 - 1890
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Antibacterial agents | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Arrhythmias, Cardiac - chemically induced | United States | Humans | Middle Aged | Male | Risk | Death, Sudden, Cardiac - etiology | Incidence | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Cardiovascular Diseases - mortality | Adult | Female | Anti-Bacterial Agents - adverse effects | Cardiovascular Diseases - chemically induced | Retrospective Studies | Medicaid | Cohort Studies | Dose-response relationship (Biochemistry) | Causes of | Complications and side effects | Cardiovascular diseases | Azithromycin | Levofloxacin | Hospitals | Antibiotics | Amoxicillin | Macrolide antibiotics | Death | Ciprofloxacin | Index Medicus | Abridged Index Medicus
Journal Article
Biosensors & bioelectronics, ISSN 0956-5663, 05/2020, Volume 155, pp. 112098 - 112098
Urine | Plasma | Molecularly imprinted polymers | Electrochemical sensor | Tears | Azithromycin | Physical Sciences | Chemistry | Nanoscience & Nanotechnology | Life Sciences & Biomedicine | Electrochemistry | Science & Technology - Other Topics | Biophysics | Chemistry, Analytical | Biotechnology & App